Loading...
XSHE
002932
Market cap603mUSD
Dec 05, Last price  
18.36CNY
1D
0.60%
1Q
-3.52%
IPO
60.07%
Name

Wuhan Easy Diagnosis Biomedicine Co Ltd

Chart & Performance

D1W1MN
XSHE:002932 chart
P/E
57.29
P/S
12.20
EPS
0.32
Div Yield, %
0.65%
Shrs. gr., 5y
1.50%
Rev. gr., 5y
14.08%
Revenues
350m
-53.30%
1,218,0517,096,03325,947,47857,802,45495,341,627140,979,148165,123,343176,381,394181,155,372959,099,1962,829,829,54610,530,277,815749,536,774350,061,800
Net income
75m
-0.54%
253,2391,401,8697,322,14221,539,67035,596,51559,692,00065,492,64761,419,87541,525,796468,927,7941,413,224,4344,208,496,91374,925,91674,519,615
CFO
-85m
L
01,032,5766,296,10016,474,00045,021,65058,859,24246,496,34553,671,44622,485,878359,682,4491,127,006,1474,012,848,413392,498,061-85,046,439
Dividend
May 28, 20240.12 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and diagnostic equipment in China and internationally. Its products portfolio includes molecular diagnostic products, such as drug metabolism genetic testing and pathogen nucleic acid detection kits; and immunodiagnostic and blood gas diagnosis products. The company also provides emergency and critical illness information solutions, including information software products, supporting hardware, and certification consulting services; and third-party medical inspection services. It offers products in the areas of cardiovascular, kidney, infectious, diabetes, endocrine and metabolic, obstetrics, and gynecology diseases, as well as prenatal and postnatal care, health checkups, thyroid, hormones, blood gas, coagulation, drug metabolism, pathogen detection. The company was founded in 2008 and is based in Wuhan, China.
IPO date
Jul 10, 2018
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT